What is the recommended Survodutide dosage?

Survodutide dosing varies by experience level. Beginners typically start at 600mcg weekly, moderate users at 2400mcg weekly, and aggressive protocols use 4800mcg weekly.

How do you reconstitute Survodutide?

Survodutide typically comes in 10mg vials. Add 2mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of Survodutide?

The half-life of Survodutide is ~6 days. This determines how frequently you need to dose for consistent blood levels.

Survodutide

Weight LossInjectionPhase 3Grade B~6 days half-life

GLP-1 AgonistWeight ManagementAppetite RegulationFat LossAnti-Fibrotic

Benefits

Up to 80% liver fat reduction

Dual-action weight loss mechanism

Leading candidate for MASH/fatty liver treatment

Significant body weight reduction

Weekly dosing

Half-Life

~6 days

Route

Injection

Frequency

Weekly

Vial Sizes

10mg

BAC Water

2mL

Safety Grade

Grade B

Open Survodutide Dosage Calculator

Calculate exact syringe units for your vial and dose

About Survodutide

Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. What sets it apart is its remarkable effect on liver fat — clinical trials showed up to 80% reduction in liver fat content, making it a leading candidate for MASH (metabolic dysfunction-associated steatohepatitis). It also produces significant weight loss through combined appetite suppression and thermogenic fat burning.

Who Should Consider Survodutide

Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
Patients with MASH/NASH and liver fibrosis (F1-F3)
Adults with obesity and type 2 diabetes (SYNCHRONIZE-2 population)
Patients who have not responded adequately to GLP-1-only agonists
Adults with obesity-related cardiovascular risk factors

How Survodutide Works

Survodutide is a dual glucagon receptor (GCGR) and GLP-1 receptor agonist. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. Glucagon receptor activation increases hepatic fat oxidation, boosts energy expenditure through thermogenesis, and promotes lipolysis. This dual mechanism produces both weight loss and direct liver fat reduction — a key differentiator from GLP-1-only agonists. A C18 diacid modification enables albumin binding, extending the half-life to support weekly dosing.

What to Expect

Weeks 1-4

Starting dose 0.6mg weekly. Mild appetite suppression may begin. GI side effects (nausea, diarrhea) are most common during early titration. Minimal weight loss expected — this is a tolerability phase.

Weeks 5-12

Dose escalated through 1.2mg and 1.8mg. Appetite reduction becomes more noticeable. Early weight loss of 2-4%. GI symptoms typically peak during each dose increase then improve.

Weeks 13-20

Continued escalation toward target dose (3.6mg or 6.0mg). Steady weight loss accumulating. Liver fat reduction measurable on imaging in MASH patients.

Weeks 21-46

Maintenance at target dose. Phase 2 data showed up to 14.9% weight loss at 46 weeks (4.8mg, planned treatment analysis) and nearly 19% in completers. MASH trial showed up to 80% liver fat reduction at 48 weeks.

Weeks 47-76

Extended maintenance phase (Phase 3 SYNCHRONIZE design). Further weight loss and metabolic improvements expected. Long-term outcomes data pending from ongoing trials.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	600mcg	Weekly
Moderate	2,400mcg	Weekly
Aggressive	4,800mcg	Weekly

Note: Dual GLP-1/glucagon agonist by Boehringer Ingelheim. Up to 80% liver fat reduction in MASH trials. Titrate from 0.6mg weekly.

How to Inject Survodutide

Inject subcutaneously once weekly into abdomen, thigh, or upper arm. Rotate injection sites. Follow a slow dose-escalation schedule: start at 0.6mg weekly and titrate over 20 weeks to the target dose (3.6mg or 6.0mg) to minimize GI side effects.

Cycling Protocol

On Period

76 weeks

Off Period

0 weeks

Based on SYNCHRONIZE Phase 3 trial design (76 weeks). Titrate from 0.6mg weekly over 20 weeks. Long-term maintenance data not yet available.

Pharmacokinetics

Half-Life

144h

Bioavailability

SC: ~80-90% (preclinical)

Tmax

2-3 days

Data Confidence

moderate

Source: Phase 1/2 PK data; t½ ~109-115h median, ~6 days reported (albumin-bound C18 diacid conjugate)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Nausea, diarrhea, vomiting (dose-dependent). Decreased appetite. Slow titration recommended to minimize GI effects.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
History of pancreatitis or active pancreatitis
Pregnancy or planning to become pregnant
Breastfeeding
Known hypersensitivity to survodutide or any excipients
Severe gastrointestinal disease (e.g., gastroparesis)
Decompensated cirrhosis (limited safety data available)

Drug Interactions

Insulin and sulfonylureas — increased hypoglycemia risk; dose reduction often needed
Other GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) — do not combine; overlapping mechanism
Oral contraceptives — reduced efficacy due to delayed gastric emptying; use barrier method during titration
Oral medications with narrow therapeutic index (e.g., warfarin) — monitor closely due to delayed gastric emptying
Anticholinergic drugs — may compound GI side effects and further slow gastric motility